<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628160</url>
  </required_header>
  <id_info>
    <org_study_id>05-SS-JFDEZ-1</org_study_id>
    <secondary_id>EUDRACAT-2005-000439-56</secondary_id>
    <secondary_id>2005-000439-56</secondary_id>
    <nct_id>NCT00628160</nct_id>
  </id_info>
  <brief_title>Terlipressin in Septic Shock in Cirrhosis</brief_title>
  <official_title>Effects on Survival of Terlipressin Administration in Cirrhotic Patients With Severe Sepsis or Septic Shock. A Randomized, Open Labelled Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a frequent and severe complication in cirrhosis. Current mortality rate
      ranges between 50 and 80% of cases. Refractory shock, hepatorenal failure and variceal
      bleeding are the main causes of death of these patients. Terlipressin administration could
      prevent these complications and improve survival in this setting.

      Aim: To evaluate the effects of terlipressin administration on hospital survival in cirrhotic
      patients with severe sepsis or septic shock.

      Methods: Prospective, open labelled, controlled trial evaluating 72 cirrhotic patients with
      severe sepsis or septic shock who will be randomized to receive terlipressin plus
      alpha-adrenergic drugs or only alpha-adrenergic drugs at shock diagnosis. Patients will be
      submitted to continuous systemic hemodynamic monitoring (S. Ganz catheter or Vigileo).
      Changes in vasoactive systems and cytokines levels will be also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open labelled, RCT evaluating 72 cirrhotic patients with severe sepsis or septic
      shock (36 per arm) who were randomized to receive terlipressin plus alpha-adrenergic drugs or
      alpha-adrenergic drugs in the first 24h after septic shock diagnosis. Impact of terlipressin
      administration on shock reversal, changes in vasoactive systems, inflammatory response,
      incidence of variceal bleeding and type-1 HRS and ICU and hospital mortality was investigated
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital survival</measure>
    <time_frame>Hospitalization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refractory shock</measure>
    <time_frame>ICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variceal bleeding</measure>
    <time_frame>ICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatorenal syndrome</measure>
    <time_frame>Hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Terlipressin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.</description>
    <arm_group_label>Terlipressin group</arm_group_label>
    <other_name>Glypressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha adrenergic drugs</intervention_name>
    <description>Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Dopamine and/or norepinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 80 years;

          2. Diagnosis of cirrhosis based on histology or on clinical, laboratory and
             ultrasonographical data;

          3. Diagnosis of septic shock based on the presence of data compatible with systemic
             inflammatory response syndrome, a mean arterial pressure below 60 mmHg during more
             than 1 hour despite adequate fluid resuscitation, and need for circulatory support
             with vasopressor drugs.

        Exclusion Criteria:

          1. More than 24 hours of evolution of the shock;

          2. Cardiac index &lt; 2,5 l/min;

          3. History of HIV infection or clinically relevant pulmonary, renal or cardiac disease
             except for atrial fibrillation;

          4. Pregnancy;

          5. Advanced hepatocellular carcinoma (Milan criteria);

          6. Previous history of transplantation;

          7. Uncontrolled gastrointestinal bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Arroyo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2008</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Vicente Arroyo Perez</investigator_full_name>
    <investigator_title>Senior Hepatologist Consultant</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We are currently writing the manuscript</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

